Table 7.
Clinical trials using cytotoxic T lymphocytes.
| Study | Phase | Patients (n) | Results | Ref. |
|---|---|---|---|---|
| Tsuboi et al. (2003) | I | 10 | CR: 1 PR: 4 Median survival: 5 months Overall response rate: 50% |
[76] |
| Wood et al. (2000) | I | 9 | PR: 3 Survival >4 years: 2 |
[118] |
| Plautz et al. (2000) | I | 9 | PR: 3 (1 GBM and 2 grade III survival >4 years) |
[119] |
| Sloan et al. (2000) | I | 19 | CR: 1 PR: 7 Median survival: 12 months |
[120] |
| Quattrocchi et al. (1999) | I | 6 | CR: 1 PR: 2 |
[75] |
| Tsurushima et al. (1999) | I | 4 | PR: 3 SD: 1 |
[121] |
| Plautz et al. (1998) | I | 10 | SD: 1 4 patients alive after 1 year |
[122] |
| Kruse et al. (1997) | I | 5 | Transient toxicities: Survival (AO) >30 months Survival (AA) >28 months |
[123] |
| Holladay et al. (1996) | I | 15 | No PR or SD Disease-free survival >8 months: 7 |
[124] |
| Kitahara et al. (1987) | I | 5 | PR: 2 1 patient alive >104 weeks |
[125] |
AA: Anaplastic astrocytoma; AO: Anaplastic oligodendroglioma; CR: Complete response; GBM: Glioblastoma multiforme; PR: Partial response; SD: Stable disease.